Vimovo Related Published Studies
Well-designed clinical trials related to Vimovo (Esomeprazole / Naproxen)
Impact of a Fixed-Dose Combination of Naproxen and Esomeprazole Magnesium on Serum Thromboxane B(2) Inhibition by Low-Dose Aspirin Over 5 Days in Healthy Adults: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Noninferiority Trial. [2011.11.09]
Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials. [2011.06]
Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers. [2011.04]
Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in
patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs.
enteric-coated naproxen alone. [2010]
Well-designed clinical trials possibly related to Vimovo (Esomeprazole / Naproxen)
Primary prevention of adverse gastroduodenal effects from short-term use of non-steroidal anti-inflammatory drugs by omeprazole 20 mg in healthy subjects: a randomized, double-blind, placebo-controlled study. [2008.08]
Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. [2008.05]
Other research related to Vimovo (Esomeprazole / Naproxen)
A fixed-dose combination of naproxen and esomeprazole magnesium has comparable upper gastrointestinal tolerability to celecoxib in patients with osteoarthritis of the knee: Results from two randomized, parallel-group, placebo-controlled trials. [2011.12]
Pharmacokinetics and Relative Bioavailability of a Fixed-Dose Combination of Enteric-Coated Naproxen and Non-Enteric-Coated Esomeprazole Magnesium. [2011.05.31]
Naproxen/esomeprazole fixed-dose combination: for the treatment of arthritic symptoms and to reduce the risk of gastric ulcers. [2011.03.01]
Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone. [2010.08]
Clinical trial: evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed-dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric-coated esomeprazole 20 mg: a randomized, open-label, Phase I study in healthy volunteers. [2010.08]
Clinical trial: evaluation of gastric acid suppression with three doses of
immediate-release esomeprazole in the fixed-dose combination of PN 400
(naproxen/esomeprazole magnesium) compared with naproxen 500 mg and
enteric-coated esomeprazole 20 mg: a randomized, open-label, Phase I study in
healthy volunteers. [2010]
Other possibly related research studies
Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. [2009.07.14]
Hydroxychloroquine-induced hyperpigmentation: the staining pattern. [2008.12]
Gateways to clinical trials. [2010.12]
Angioedema after nonsteroidal antiinflammatory drug initiation in a patient stable on an angiotensin-converting-enzyme inhibitor. [2010.08.15]
|
